News
CSL announces it will oppose FTC in court challenge, reaffirms intent to acquire Talecris
MELBOURNE, Australia – CSL Limited said in a press release today that the company will “vigorously oppose” the US Federal Trade Commission’s attempt to block CSL’s proposed acquisition of Talecris Biotherapeutics.
Brian McNamee, MD, the CEO and Managing Director of CSL Limited, said, “We strongly disagree with the FTC’s decision to challenge the deal. CSL intends to vigorously oppose the FTC’s actions. The FTC has failed to recognize that this combination is pro-competitive, provides significant efficiencies that will improve
the supply of biotherapies, and is beneficial to the patient community. The Commission failed to take into account the substantial remedies that were offered by CSL which addressed their concerns especially in relation to plasma supply, Alpha-1 and RhoD.”
McNamee went on to say, “I’m particularly surprised and disappointed with the Commission’s theory that there is any coordination in the plasma industry. This sector is intensely competitive with manufacturers rapidly expanding.”
